Biosimilar G-CSF Effective in Preventing Febrile Neutropenia in Sarcoma

Share this content:
Filgrastim-sndz, a biosimilar product to the G-CSF filgrastim, appears to be effective in the prevention of febrile neutropenia.
Filgrastim-sndz, a biosimilar product to the G-CSF filgrastim, appears to be effective in the prevention of febrile neutropenia.

Filgrastim-sndz, a biosimilar product to the granulocyte colony-stimulating factor (G-CSF) filgrastim, appears to be effective in the prevention of febrile neutropenia for, and for reducing the risk of hospitalization of, patients with soft tissue sarcoma receiving epirubicin and ifosfamide, according to a study published in Supportive Care in Cancer.1

Anthracycline and ifosfamide-based chemotherapy are often used for soft tissue sarcoma in both early and advanced treatment settings.

Prophylaxis with G-CSF is typically required to reduce the severity of chemotherapy-induced neutropenia; researchers evaluated the efficacy and safety of filgrastim-sndz in this patient population.

Investigators analyzed data from 67 patients with soft tissue sarcoma who received epirubicin and ifosfamide between 2003 and 2013. As prophylaxis for chemotherapy-induced neutropenia, patients also received filgrastim, filgrastim-sndz, or lenograstim, which is not approved in the United States.

A total of 44% of patients in the filgrastim-sndz group experienced febrile neutropenia, in contrast with 40% in the filgrastim group and 45.5% in the lenograstim group.

RELATED: Researchers Determine Best Metrics for Predicting Survival in Ewing Sarcoma

The incidence of all grade and grade 4 neutropenia was similar across the 3 groups, as were the safety profiles.

The use of filgrastim-sndz achieved of cost savings of €225.25 over the filgrastim reference product.

Reference

  1. Bongiovanni A, Monti M, Foca F, et al. Recombinant granulocyte colony-stimulating factor (rG-CSF) in the management of neutropenia induced by anthracyclines and ifosfamide in patients with soft tissue sarcomas (NEUSAR). Supp Care Cancer. 2016 Aug 27. doi: 10.1007/s00520-016-3390-0 [Epub ahead of print]

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters